Effect of Cyclooxygenase-2 Inhibitor on CD4+ CD25+ Regulatory T Cells in Mouse Hepatocellular Carcinoma

XU Da-heng, CHEN Lin, TANG Cheng-wei, WANG Chun-hui, MENG Wen-tong

Abstract


To investigate the effect of celecoxib on regulatory T cells (Treg) in mouse hepatocellular carcinoma (HCC). Methods Total of 40 mice was divided into two subgroups, normal animal groups include control and celecoxib group, HCC groups include control and celecoxib group. 30 mg/kg of celecoxib were given daily for 24 days for celecoxib groups. All mice were sacrificed after 24 days treatment and the removed tumor weight were measured. By detecting CD4 and CD25 with flow cytometry, the level of Treg in peripheral blood was determined. The expressions of Forkhead/winged helix transcription factor-3 (Foxp3) protein in the tumor infiltrating lymphocytes (TILs) and cyclooxygenase-2(COX-2) protein in tumor tissue were measured by immunohistochemistry techniques. Results The mean weight of tumor in celecoxib group is much lower than that of control group [(0.82±0.30) g vs. (1.41±0.63) g, P<0.05]. The percentage of Treg in total CD4+T cells isolated from the peripheral blood of HCC animals in control group was higher than that of normal control group [(4.26±0.89)% vs. (3.01±0.65)%, P<0.05]. After treatment with celecoxib, the percentage of Treg was decreased [(3.04±0.74)% vs. (4.26±0.89)%, P<0.05] and the percentage of Foxp3 positive cell in TILs was also decreased [(8.87±3.72)% vs. (30.78±9.26)%, P<0.05]. The tumor tissue COX-2 protein expression in celecoxib group was lower than in that of control group [IOD (2.90±1.030) vs. (6.63±2.279), P<0.01)] and the changing of COX-2 in tumor tissue was according to Treg in the peripheral blood. Conclusion Treg cells are increased in the peripheral blood of HCC mice and COX-2 inhibitor could decrease the percentage of Treg cell in the peripheral blood or TILs.

 

Keywords: CD4+ CD25+ regulatory T cell, Forkhead/winged helix transcription factor-3, Cyclooxygenase-2, Hepatocellular carcinoma

 

Full Text:

PDF


References


Robinson JK. Colimon LM, Isaacson KB. Postoperative adhesiolysis therapy for intrauterine adhesions ( Asherman ‘ s syndrome). Fertil Steril,2008;90(2) :409-414.

Hynes RO. The extracellular matrix: not just pretty fibrils. Science,2009?326(5957): 1216-1219.

Mariasegaram M, Tesch GH, Verhardt S, et al. Lefty antagonises TGF-£l induced epithelial-mesenchymal transition in tubular epithelial cells. Biochem Biophys Res Commun. 2010;393(4):855-859.

Hinz B. Tissue stiffness, latent TGF1 activation, and mechanical signal transduction; implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep, 2009;11(2):120-126.

Wgster D, Zhu C, Bjrck HM, et al. Effects of PIXjF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression. Atherosclerosis,2009;202(2) :415-423.

Thomson AJ, Abbott JA, Kingston A, et al. Fluoroscopically guided synechiolysis for patients with Asherman ’ s syndrome: menstrual and fertility outcomes. Fertil Steril, 2007; 87 ( 2 ); 405-410.

Yu D. Li TC, Xia E, et al. Factors affecting reproductive outcome of hysteroscopic adhesiolysis for Asherman ‘ s syndrome. Fertil Steril,2008;89(3);715-724.

Pabuccu R, Onalan G, Kaya С, et al. Efficiency and pregnancy outcome of serial intrauterine device-guided hysteroscopic adhesiolysis of intrauterine synechiae. Fertil Steril, 2008; 90 (5):1973-1977.

Trappmann В, Gautrot JE. Connelly JT, et al. Extracellular- matrix tethering regulates stem-cell fate. Nat Mater, 2012; 11 (7) ;642-649.

Tashiro Y, Nishida C, Sato-Kusubata K. et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood,2012;119(26):6382-6393.

Aucella F, Margaglione M, Vigilante M, et al. PAI-1 4G/5G and ACE I/D gene polymorphisms and the occurrence of myocardial infarction in patients on intermittent dialysis. Nephrol Dial Transplant,2003; 18(6): 1142-1146.

Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood, 2010;116(1) : 113-121.

Paolillo R, Iovene M, Romano CC, et al. Induction of VEGF and MMP-9 expression by toll-like receptor 2/4 in human endothelial cells infected with Chlamydia pneumoniae. Int J Immunopathol Pharmacol,2012;25(2);377-386.

Meng Y, Liu В, Lei N, et al. Alpha-momorcharin possessing high immunogenicity. immunotoxicity and hepatotoxicity in SD rats. J Ethnopharmacol.2012; 139(1):590-598.

Li ME, Chen YW, Liu ZY, et al. Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Bioch Bioph Sin, 2009; 41 ( 9); 792- 799.

Bian XX. Shen FB,Chen YW. et al. PEGylation of alpha- momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential. Biotechnol Lett, 2010;32(2);883-890.

Chapman AP. PEGylated antibodies and antibody fragments for improved therapy; a review. Adv Drug Del Rev» 2002; 54 (4);531-545.

Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov,2003;2(5):347-360.

Chan WY, Huang H, Tam SC. Receptor-mediated endocytosis of trichosanthin in choriocarcinoma cells. Toxicology,2003; 186 (2):191-203.

Zheng G, Baehinsky DR, Kovie IS, et al. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor- associated protein (RAP). J Histochem Cytochem, 1994; 42 (4):531-536.


Refbacks

  • There are currently no refbacks.